{
  "DOI": "10.1186/s40246-023-00568-3",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-023-00568-3",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eClopidogrel is a widely prescribed prodrug that requires activation via specific pharmacogenes to exert its anti-platelet function. Genetic variations in the genes encoding its transporter, metabolizing enzymes, and target receptor lead to variability in its activation and platelet inhibition and, consequently, its efficacy. This variability increases the risk of secondary cardiovascular events, and therefore, some variations have been utilized as genetic biomarkers when prescribing clopidogrel.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eMethods\u003c/jats:title\u003e\n                \u003cjats:p\u003eOur study examined clopidogrel-related genes \u003cjats:italic\u003e(CYP2C19, ABCB1, PON1,\u003c/jats:italic\u003e and \u003cjats:italic\u003eP2Y12R)\u003c/jats:italic\u003e in a cohort of 298 healthy Emiratis individuals. The study used whole exome sequencing (WES) data to comprehensively analyze pertinent variations of these genes, including their minor allele frequencies, haplotype distribution, and their resulting phenotypes.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eOur data shows that approximately 37% (\u003cjats:italic\u003en\u003c/jats:italic\u003e = 119) of the cohort are likely to benefit from the use of alternative anti-platelet drugs due to their classification as intermediate or poor \u003cjats:italic\u003eCYP2C19\u003c/jats:italic\u003e metabolizers. Additionally, more than 50% of the studied cohort exhibited variants in \u003cjats:italic\u003eABCB1, PON1, and P2YR12\u003c/jats:italic\u003e genes, potentially influencing clopidogrel’s transport, enzymatic clearance, and receptor performance.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusions\u003c/jats:title\u003e\n                \u003cjats:p\u003eRecognizing these alleles and genotype frequencies may explain the clinical differences in medication response across different ethnicities and predict adverse events. Our findings underscore the need to consider genetic variations in prescribing clopidogrel, with potential implications for implementing personalized anti-platelet therapy among Emiratis based on their genetic profiles.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "568"
  ],
  "article-number": "2",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "31 October 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "19 December 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "3 January 2024"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethical approvals and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The study was conducted in accordance with the Declaration of Helsinki and approved by the Department of Health-AbuDhabi for the Data from the UAEU (DOH/CVDC/2022/1450), While the Data from KU, approved by Dubai Scientific Research Ethical Committee with the identification code (DSREC-07/2020_19, A-2021-070). Informed consent was obtained from all subjects involved in the study."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Not applicable."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "The authors declare that they have no competing interests."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Khasawneh",
      "given": "Lubna Q.",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Alsafar",
      "given": "Habiba",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Alblooshi",
      "given": "Hiba",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Allam",
      "given": "Mushal",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Patrinos",
      "given": "George P.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Ali",
      "given": "Bassam R.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2024,
        1,
        3
      ]
    ],
    "date-time": "2024-01-03T13:02:25Z",
    "timestamp": 1704286945000
  },
  "deposited": {
    "date-parts": [
      [
        2024,
        1,
        3
      ]
    ],
    "date-time": "2024-01-03T13:06:15Z",
    "timestamp": 1704287175000
  },
  "funder": [
    {
      "award": [
        "1570604941 (UAEU code 21M139)",
        "1570604941 (UAEU code 21M139)"
      ],
      "name": "Ministry of Education, United Arab Emirates"
    },
    {
      "award": [
        "VRI-20-10",
        "VRI-20-10"
      ],
      "name": "ASPIRE, the technology program management pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), via the ASPIRE Precision Medicine Research Institute."
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        1,
        4
      ]
    ],
    "date-time": "2024-01-04T00:18:56Z",
    "timestamp": 1704327536634
  },
  "is-referenced-by-count": 0,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2024,
        1,
        3
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2024,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2024,
            1,
            3
          ]
        ],
        "date-time": "2024-01-03T00:00:00Z",
        "timestamp": 1704240000000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2024,
            1,
            3
          ]
        ],
        "date-time": "2024-01-03T00:00:00Z",
        "timestamp": 1704240000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00568-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-023-00568-3/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00568-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2024,
        1,
        3
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2024,
        1,
        3
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1007/s40262-014-0230-6",
      "author": "XL Jiang",
      "doi-asserted-by": "publisher",
      "first-page": "147",
      "issue": "2",
      "journal-title": "Clin Pharmacokinet",
      "key": "568_CR1",
      "unstructured": "Jiang XL, Samant S, Lesko LJ, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015;54(2):147–66.",
      "volume": "54",
      "year": "2015"
    },
    {
      "DOI": "10.4137/CMC.S4323",
      "author": "C Terpening",
      "doi-asserted-by": "publisher",
      "first-page": "117",
      "journal-title": "Clin Med Insights Cardiol",
      "key": "568_CR2",
      "unstructured": "Terpening C. Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol. 2010;4:117–28.",
      "volume": "4",
      "year": "2010"
    },
    {
      "DOI": "10.3390/molecules26071987",
      "doi-asserted-by": "crossref",
      "key": "568_CR3",
      "unstructured": "Akkaif MA, Daud NAA, Sha’aban A, Ng ML, Abdul Kader MAS, Noor DAM, et al. The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD). Molecules. 2021;26(7)."
    },
    {
      "DOI": "10.1016/j.clpt.2006.07.007",
      "author": "D Taubert",
      "doi-asserted-by": "publisher",
      "first-page": "486",
      "issue": "5",
      "journal-title": "Clin Pharmacol Ther",
      "key": "568_CR4",
      "unstructured": "Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80(5):486–501.",
      "volume": "80",
      "year": "2006"
    },
    {
      "DOI": "10.1177/2042098611422559",
      "author": "TM Polasek",
      "doi-asserted-by": "publisher",
      "first-page": "253",
      "issue": "6",
      "journal-title": "Ther Adv drug Saf",
      "key": "568_CR5",
      "unstructured": "Polasek TM, Doogue MP, Miners JO. Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Ther Adv drug Saf. 2011;2(6):253–61.",
      "volume": "2",
      "year": "2011"
    },
    {
      "DOI": "10.1371/journal.pone.0026035",
      "author": "AE Garcia",
      "doi-asserted-by": "publisher",
      "issue": "10",
      "journal-title": "PLoS ONE",
      "key": "568_CR6",
      "unstructured": "Garcia AE, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP. Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis. PLoS ONE. 2011;6(10): e26035.",
      "volume": "6",
      "year": "2011"
    },
    {
      "DOI": "10.1093/ehjcvp/pvz045",
      "author": "JP Lewis",
      "doi-asserted-by": "publisher",
      "first-page": "203",
      "issue": "4",
      "journal-title": "Eur Hear J Cardiovasc Pharmacother",
      "key": "568_CR7",
      "unstructured": "Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Hear J Cardiovasc Pharmacother. 2020;6(4):203–10.",
      "volume": "6",
      "year": "2020"
    },
    {
      "DOI": "10.3389/fonc.2020.576559",
      "author": "A Seelig",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Front Oncol",
      "key": "568_CR8",
      "unstructured": "Seelig A. P-Glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers. Front Oncol. 2020;10:1–16.",
      "volume": "10",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.gpb.2016.03.008",
      "author": "S Ahmed",
      "doi-asserted-by": "publisher",
      "first-page": "298",
      "issue": "5",
      "journal-title": "Genom Proteom Bioinf",
      "key": "568_CR9",
      "unstructured": "Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom Proteom Bioinf. 2016;14(5):298–313.",
      "volume": "14",
      "year": "2016"
    },
    {
      "DOI": "10.1515/dmpt-2018-0006",
      "author": "KB Mirzaev",
      "doi-asserted-by": "publisher",
      "first-page": "109",
      "issue": "3",
      "journal-title": "Drug Metab Pers Ther",
      "key": "568_CR10",
      "unstructured": "Mirzaev KB, Rytkin E, Ryzhikova KA, Grishina EA, Sozaeva ZA, Fedorinov DS, et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metab Pers Ther. 2018;33(3):109–18.",
      "volume": "33",
      "year": "2018"
    },
    {
      "DOI": "10.3390/jpm8010008",
      "doi-asserted-by": "crossref",
      "key": "568_CR11",
      "unstructured": "Brown SA, Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. J Pers Med. 2018;8(1)."
    },
    {
      "DOI": "10.1016/j.ahj.2010.06.039",
      "author": "KA Tiroch",
      "doi-asserted-by": "publisher",
      "first-page": "506",
      "issue": "3",
      "journal-title": "Am Heart J",
      "key": "568_CR12",
      "unstructured": "Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schömig A, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010;160(3):506–12.",
      "volume": "160",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.etap.2015.03.001",
      "author": "S Mitra",
      "doi-asserted-by": "publisher",
      "first-page": "1051",
      "issue": "3",
      "journal-title": "Environ Toxicol Pharmacol",
      "key": "568_CR13",
      "unstructured": "Mitra S, Khurana P, Panmei T, Kshatriya GK. Allele frequencies of PON1 Q192R polymorphism in four populations of India. Environ Toxicol Pharmacol. 2015;39(3):1051–6.",
      "volume": "39",
      "year": "2015"
    },
    {
      "DOI": "10.3390/nu14142842",
      "doi-asserted-by": "crossref",
      "key": "568_CR14",
      "unstructured": "Otocka-Kmiecik A. Effect of carotenoids on paraoxonase-1 activity and gene expression. Nutrients. 2022;14(14)."
    },
    {
      "DOI": "10.1289/ehp.6105",
      "author": "J Chen",
      "doi-asserted-by": "publisher",
      "first-page": "1403",
      "issue": "11",
      "journal-title": "Environ Health Perspect",
      "key": "568_CR15",
      "unstructured": "Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect. 2003;111(11):1403–9.",
      "volume": "111",
      "year": "2003"
    },
    {
      "DOI": "10.1097/MD.0000000000006553",
      "author": "M Li",
      "doi-asserted-by": "publisher",
      "issue": "14",
      "journal-title": "Medicine",
      "key": "568_CR16",
      "unstructured": "Li M, Wang H, Xuan L, Shi X, Zhou T, Zhang N, et al. Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. Medicine. 2017;96(14): e6553.",
      "volume": "96",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41598-020-78231-3",
      "author": "ZN Al-Mahayri",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "568_CR17",
      "unstructured": "Al-Mahayri ZN, Patrinos GP, Wattanapokayakit S, Iemwimangsa N, Fukunaga K, Mushiroda T, et al. Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations. Sci Rep. 2020;10(1):1–15. https://doi.org/10.1038/s41598-020-78231-3.",
      "volume": "10",
      "year": "2020"
    },
    {
      "DOI": "10.3390/jpm12010104",
      "doi-asserted-by": "crossref",
      "key": "568_CR18",
      "unstructured": "Jarrar Y, Lee SJ. Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates. vol. 12, Journal of personalized medicine. Switzerland; 2022."
    },
    {
      "DOI": "10.1002/cpt.2526",
      "author": "CR Lee",
      "doi-asserted-by": "publisher",
      "first-page": "959",
      "issue": "5",
      "journal-title": "Clin Pharmacol Ther",
      "key": "568_CR19",
      "unstructured": "Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959–67.",
      "volume": "112",
      "year": "2022"
    },
    {
      "DOI": "10.1155/2019/5897505",
      "author": "X Pan",
      "doi-asserted-by": "publisher",
      "first-page": "5897505",
      "journal-title": "Biomed Res Int",
      "key": "568_CR20",
      "unstructured": "Pan X, Huang L, Li M, Mo D, Liang Y, Liu Z, et al. The association between PON1 (Q192R and L55M) gene polymorphisms and risk of cancer: a meta-analysis based on 43 studies. Biomed Res Int. 2019;2019:5897505.",
      "volume": "2019",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.jmoldx.2018.01.011",
      "author": "VM Pratt",
      "doi-asserted-by": "publisher",
      "first-page": "269",
      "issue": "3",
      "journal-title": "J Mol Diagnost",
      "key": "568_CR21",
      "unstructured": "Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagnost. 2018;20(3):269–76. https://doi.org/10.1016/j.jmoldx.2018.01.011.",
      "volume": "20",
      "year": "2018"
    },
    {
      "DOI": "10.1002/cpt.1973",
      "author": "MR Botton",
      "doi-asserted-by": "publisher",
      "first-page": "352",
      "issue": "2",
      "journal-title": "Clin Pharmacol Ther",
      "key": "568_CR22",
      "unstructured": "Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agúndez JAG, et al. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021;109(2):352–66.",
      "volume": "109",
      "year": "2021"
    },
    {
      "key": "568_CR23",
      "unstructured": "Dean L. Carisoprodol therapy and CYP2C19 genotype. Med Genet Summ. 2012;(MD):1–19."
    },
    {
      "DOI": "10.1159/000513753",
      "author": "AT Rahma",
      "doi-asserted-by": "publisher",
      "first-page": "99",
      "issue": "3–4",
      "journal-title": "Public Health Genom",
      "key": "568_CR24",
      "unstructured": "Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Al-Maskari F. Stakeholders’ interest and attitudes toward genomic medicine and pharmacogenomics implementation in the United Arab Emirates: a qualitative study. Public Health Genom. 2021;24(3–4):99–109.",
      "volume": "24",
      "year": "2021"
    },
    {
      "DOI": "10.1186/s40246-022-00417-9",
      "author": "ZN Al-Mahayri",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Hum Genomics",
      "key": "568_CR25",
      "unstructured": "Al-Mahayri ZN, Khasawneh LQ, Alqasrawi MN, Altoum SM, Jamil G, Badawi S, et al. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. Hum Genomics. 2022;16(1):1–12.",
      "volume": "16",
      "year": "2022"
    },
    {
      "DOI": "10.1186/s40246-023-00509-0",
      "author": "AT Rahma",
      "doi-asserted-by": "publisher",
      "first-page": "63",
      "issue": "1",
      "journal-title": "Hum Genom",
      "key": "568_CR26",
      "unstructured": "Rahma AT, Ali BR, Patrinos GP, Ahmed LA, Elbarazi I, Abdullahi AS, et al. Knowledge, attitudes, and perceptions of the multi-ethnic population of the United Arab Emirates on genomic medicine and genetic testing. Hum Genom. 2023;17(1):63.",
      "volume": "17",
      "year": "2023"
    },
    {
      "DOI": "10.1186/s40246-021-00361-0",
      "doi-asserted-by": "crossref",
      "key": "568_CR27",
      "unstructured": "Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Elsheik M, et al. Development of the pharmacogenomics and genomics literacy framework for pharmacists. Hum Genomics. 2021;15(1):62"
    },
    {
      "DOI": "10.3390/jpm10030134",
      "doi-asserted-by": "crossref",
      "key": "568_CR28",
      "unstructured": "Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Al Maskari F. Genomics and pharmacogenomics knowledge, attitude and practice of pharmacists working in United Arab Emirates: findings from focus group discussions-a qualitative study. J Pers Med. 2020;10(3)."
    },
    {
      "DOI": "10.1016/j.japh.2023.04.022",
      "author": "SM Fahim",
      "doi-asserted-by": "publisher",
      "first-page": "998",
      "issue": "4",
      "journal-title": "J Am Pharm Assoc",
      "key": "568_CR29",
      "unstructured": "Fahim SM, Alexander CSW, Qian J, Ngorsuraches S, Hohmann NS, Lloyd KB, et al. Current published evidence on barriers and proposed strategies for genetic testing implementation in health care settings: a scoping review. J Am Pharm Assoc. 2023;63(4):998–1016.",
      "volume": "63",
      "year": "2023"
    },
    {
      "DOI": "10.1186/s40246-023-00495-3",
      "author": "MI Koufaki",
      "doi-asserted-by": "publisher",
      "first-page": "51",
      "issue": "1",
      "journal-title": "Hum Genom",
      "key": "568_CR30",
      "unstructured": "Koufaki MI, Fragoulakis V, Díaz-Villamarín X, Karamperis K, Vozikis A, Swen JJ, et al. Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study. Hum Genom. 2023;17(1):51. https://doi.org/10.1186/s40246-023-00495-3.",
      "volume": "17",
      "year": "2023"
    },
    {
      "DOI": "10.1067/mcp.2001.117412",
      "author": "RB Kim",
      "doi-asserted-by": "publisher",
      "first-page": "189",
      "issue": "2",
      "journal-title": "Clin Pharmacol Ther",
      "key": "568_CR31",
      "unstructured": "Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189–99. https://doi.org/10.1067/mcp.2001.117412.",
      "volume": "70",
      "year": "2001"
    },
    {
      "DOI": "10.1097/00008571-200308000-00006",
      "author": "DL Kroetz",
      "doi-asserted-by": "publisher",
      "first-page": "481",
      "issue": "8",
      "journal-title": "Pharmacogenetics",
      "key": "568_CR32",
      "unstructured": "Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13(8):481–94.",
      "volume": "13",
      "year": "2003"
    },
    {
      "DOI": "10.1097/00008571-200208000-00004",
      "author": "K Tang",
      "doi-asserted-by": "publisher",
      "first-page": "437",
      "issue": "6",
      "journal-title": "Pharmacogenetics",
      "key": "568_CR33",
      "unstructured": "Tang K, Ngoi SM, Gwee PC, Chua JMZ, Lee EJD, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12(6):437–50.",
      "volume": "12",
      "year": "2002"
    },
    {
      "DOI": "10.2217/pgs.10.212",
      "author": "BS Haerian",
      "doi-asserted-by": "publisher",
      "first-page": "713",
      "issue": "5",
      "journal-title": "Pharmacogenomics",
      "key": "568_CR34",
      "unstructured": "Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics. 2011;12(5):713–25.",
      "volume": "12",
      "year": "2011"
    },
    {
      "DOI": "10.1001/jamaneurol.2018.4775",
      "author": "Y Pan",
      "doi-asserted-by": "publisher",
      "first-page": "552",
      "issue": "5",
      "journal-title": "JAMA Neurol",
      "key": "568_CR35",
      "unstructured": "Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon T, et al. Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial. JAMA Neurol. 2019;76(5):552–60. https://doi.org/10.1001/jamaneurol.2018.4775.",
      "volume": "76",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa0808227",
      "author": "T Simon",
      "doi-asserted-by": "publisher",
      "first-page": "363",
      "issue": "4",
      "journal-title": "N Engl J Med",
      "key": "568_CR36",
      "unstructured": "Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75. https://doi.org/10.1056/NEJMoa0808227.",
      "volume": "360",
      "year": "2009"
    },
    {
      "DOI": "10.4314/tjpr.v17i11.24",
      "doi-asserted-by": "crossref",
      "key": "568_CR37",
      "unstructured": "Rjoub M, Saleh A, Hakooz N, Imraish A, Jarrar Y, Zihlif M. CYP2C19 * 17 among Jordanian patients taking clopidogrel. 2018;17:2275–80."
    },
    {
      "DOI": "10.5144/0256-4947.2017.425",
      "author": "KK Alharbi",
      "doi-asserted-by": "publisher",
      "first-page": "425",
      "issue": "6",
      "journal-title": "Ann Saudi Med",
      "key": "568_CR38",
      "unstructured": "Alharbi KK, Alnbaheen MS, Alharbi FK, Hasanato RM, Khan IA. Q192R polymorphism in the PON1 gene and familial hypercholesterolemia in a Saudi population. Ann Saudi Med. 2017;37(6):425–32.",
      "volume": "37",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s11033-014-3798-x",
      "doi-asserted-by": "crossref",
      "key": "568_CR39",
      "unstructured": "Janicsek I, Sipeky C, Bene J, Duga B, et al. Erratum to: Significant interethnic differences in functional variants of PON1 and P2RY12 genes in Roma and Hungarian population samples. Mol Biol Rep. 2014."
    },
    {
      "DOI": "10.1177/0748233713487246",
      "author": "SZ Sunay",
      "doi-asserted-by": "publisher",
      "first-page": "1061",
      "issue": "12",
      "journal-title": "Toxicol Ind Health",
      "key": "568_CR40",
      "unstructured": "Sunay SZ, Kayaaltı Z, Bayrak T, Söylemezoğlu T. Effect of paraoxonase 1 192 Q/R polymorphism on paraoxonase and acetylcholinesterase enzyme activities in a Turkish population exposed to organophosphate. Toxicol Ind Health. 2013;31(12):1061–8. https://doi.org/10.1177/0748233713487246.",
      "volume": "31",
      "year": "2013"
    },
    {
      "DOI": "10.1007/s11033-014-3762-9",
      "author": "I Janicsek",
      "doi-asserted-by": "publisher",
      "first-page": "227",
      "issue": "1",
      "journal-title": "Mol Biol Rep",
      "key": "568_CR41",
      "unstructured": "Janicsek I, Sipeky C, Bene J, Duga B, Melegh B, Sümegi K, et al. Significant interethnic differencies in functional variants of PON1 and P2RY12 genes in Roma and Hungarian population samples. Mol Biol Rep. 2015;42(1):227–32.",
      "volume": "42",
      "year": "2015"
    },
    {
      "DOI": "10.2147/VHRM.S330766",
      "author": "D Corredor-Orlandelli",
      "doi-asserted-by": "publisher",
      "first-page": "689",
      "journal-title": "Vasc Health Risk Manag",
      "key": "568_CR42",
      "unstructured": "Corredor-Orlandelli D, Sambracos-Parrado S, Mantilla-García S, Tovar-Tirado J, Vega-Ramírez V, Mendoza-Ayús SD, et al. Association between paraoxonase-1 p.Q192R polymorphism and coronary artery disease susceptibility in the Colombian population. Vasc Health Risk Manag. 2021;17:689–99.",
      "volume": "17",
      "year": "2021"
    },
    {
      "DOI": "10.1186/s12872-022-02988-w",
      "author": "YJ Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "BMC Cardiovasc Disord",
      "key": "568_CR43",
      "unstructured": "Zhang YJ, Li DJ, Li ZY, Hu XL, Li H, Ma QL, et al. Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease. BMC Cardiovasc Disord. 2022;22(1):1–11.",
      "volume": "22",
      "year": "2022"
    },
    {
      "DOI": "10.1055/a-0622-8110",
      "author": "K Zhao",
      "doi-asserted-by": "publisher",
      "first-page": "23",
      "issue": "1",
      "journal-title": "Drug Res",
      "key": "568_CR44",
      "unstructured": "Zhao K, Yang M, Lu Y, Sun S, Li W, Li X, et al. P2Y12 polymorphisms and the risk of adverse clinical events in patients treated with clopidogrel: a meta-analysis. Drug Res. 2019;69(1):23–31.",
      "volume": "69",
      "year": "2019"
    }
  ],
  "reference-count": 44,
  "references-count": 44,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00568-3"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "The diversity and clinical implications of genetic variants influencing clopidogrel bioactivation and response in the Emirati population"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "18"
}